Novel Analgesic Breakthrough: Xinhua Pharmaceutical’s Class 1 Drug LXH-2103 Secures Clinical Approval with Medicilon’s Preclinical Support

Shandong Xinhua Pharmaceutical Co., Ltd., the core subsidiary of Shandong Hualu Holdings Co., Ltd., has obtained official clinical trial approval from the National Medical Products Administration (NMPA) for LXH-2103 Injection, its self-developed Class 1 innovative drug. The candidate is approved for clinical research in the treatment of moderate to severe postoperative pain, marking a key […]